About Fiona Adams

Fiona Adams is Executive Vice President, Managing Shareholder of the London office and the Co-Chair of the Global Corporate Practice. She primarily represents corporate clients, focusing her practice on mergers and acquisitions, and other transactional matters. Her work spans a range of industries, including pharmaceuticals, industrials, automotives, financial institutions, and media. Fiona has broad experience working on large, complex cross-border transactions.

Fiona was awarded Management Partner of the Year at the Legal Business Awards 2023, Law Firm Leader of the Year: Large Practice at the Woman & Diversity in Law Awards 2024, and Legal Leader of the Year at the Women, Influence & Power UK Awards 2024. She continues to be highly recommended by both of the leading independent guides to the legal industry, and is currently ranked in the Hall of Fame for M&A: Lower Mid-Market Deals, 100m-750m in Legal 500 UK 2025 and ranked in Band 2 of the Corporate/M&A: 100-800m category for Chambers & Partners 2025. According to Chambers & Partners 2025, Fiona “is an outstanding lawyer and a great fit with our in-house team. She is also super responsive and very easy to work with,' 'is a really strong and capable lawyer. She is very efficient and understands the core of problems' and “is very client-oriented with wide experience.' The Legal 500 2024 edition advises 'Fiona Adams is extremely hard-working and responsive. She has a vast amount of experience to tap into and does so quickly and succinctly.'

Concentrations

•Mergers and acquisitions
•Corporate transactions
•Joint ventures

Recognition & Leadership

Awards & Accolades

•Winner, Global Legal Post Women & Diversity in Law Awards, 'Law Firm Leader of the Year,' 2024
•Winner, Law.com International Women, Influence & Power in Law (WIPL) UK Awards, 'Legal Leader of the Year,' 2024
•Winner, London Legal Business Awards, “Management Partner of the Year,” 2023
•Listed, Best Lawyers in the United Kingdom, Mergers and Acquisitions Law, 2015-2025
•'Lawyer of the Year,' 2022
•Team Member, a Law360 “Product Liability Practice Group of the Year,” 2021-2022
•Listed, IFLR 1000 United Kingdom
•'Highly Regarded' M&A, 2019-2025
•'Leading Lawyers' M&A, 2017-2018
•Listed, Chambers UK Guide, Corporate/M&A, 2012-2020, 2022-2026
•Listed, Chambers Global, Corporate/ M&A (UK), 2014-2020
•Listed, Chambers Europe, 2020, 2022-2025
•Corporate/M&A: Mid-Market, 2024-2025
•Corporate/M&A: High-end Capability, 2020, 2022
•Listed, The Legal 500 United Kingdom, 2012-2026
•Corporate and Commercial - M&A: Upper Mid-Market and Premium Deals, 2012-2023
•'Leading Individual' 2023
•Corporate/M&A: Lower Mid-Market Deals, 2024-2026
•'Hall of Fame,' 2024-2026
•Listed, Euromoney's Expert Guides: 'Women in Business Law,' 2021-2022

 

Reviews for Fiona

This lawyer does not have any client reviews on Lawyers.com yet

Write a Review

Services

Areas of Law

  • Other 5
    • Corporate
    • Mergers & Acquisitions
    • Automotive
    • Food, Beverage & Agribusiness
    • Complex Torts

Practice Details

  • Firm Information
    Position
    London Co-Managing Shareholder; Co-Chair, Global Corporate & Securities Practice
    Firm Name
    Greenberg Traurig, LLP
  • Representative Cases & Transactions
    Cases
    Experience: Representative Matters: Represented TELUS, a Canadian telecoms company, in the acquisition of the Proagrica br
    , a provider of data services to agriculture companies, from the RELX Group, a British multinational information
    analytics company that also owns LexisNexis.
    Represented a multinational transport manufacturing corporation on numerous transactions including: a joint venture with a European car manufacturer to create a new generation of fully electric vans
    light commercial vehicles

    its EUR500 million three-way JV relating to the installation
    operation of a high-performance public charging network for battery electric, heavy-duty long-haul trucks
    coaches across Europe


    a joint venture relating to the development
    commercialisation of a software-defined vehicle platform.
    Advised Rentokil Initial plc, the world's leading commercial pest control services provider, on the worldwide acquisition of Cannon Hygiene business from OCS Group Limited.
    Advised Rentokil Initial plc on the purchase of the entire issued share capital of DCUKFM Holdings Limited, a leading UK commercial
    residential property remediation specialist.
    Advised Rentokil Initial plc in the circa 44 million acquisition of Urban Planters, a group operated via four companies (Urban Planters Franchise Limited, The Palfreymans Limited, Tropical Innovation Limited
    Newman's Plants Limited)
    their five subsidiaries, which were acquired immediately pre-completion along with other assets from a number of individual sellers.
    Advised MonteRock, a UAE-based investment company, in relation to its investment in a joint venture with Singapore-based hospitality group Aman, to develop
    operate the Aman hotel in Mykonos, Greece. The new joint venture entity is based in Cyprus.
    Advised a US bridging group on the acquisition of a UK modular bridging business.
    Advised Rentokil Initial plc on its joint venture agreement with Haniel & Cie. Holding Company which created a leading provider of workwear
    hygiene services in Europe with combined revenues of c. 1.1bn.
    Advised AstraZeneca plc on the sale of its small molecule antibiotics business to Pfizer for US$725m.
    Advised AstraZeneca plc on its agreement with China Medical System Holdings
    its associated company Tibet Rhodiola Pharmaceutical Holdings Co., Ltd., to divest Imdur, a mature medicine for the prevention of angina in patients with heart disease for the global market for US$190m.
    Advised AstraZeneca AB on its agreement with Grunenthal to divest the European rights to Nexium for an upfront payment of $700 million with further sales-related
    milestone payments of up to $90 million.
    Advised AstraZeneca AB on its agreement with Grunenthal to divest the global rights to Vimovo in all markets excluding the United States
    Japan for an upfront payment of $115 million
    further payments up to another $17 million.
    Advised AstraZeneca AB on its US$243 million divestment to Cheplapharm of the global rights (excluding China, Japan, USA
    Mexico) for LOSEC (omeprazole)
    associated br
    s.
    Advised AstraZeneca AB on its US$236 million sale of Atac
    to German pharma company Cheplapharm Arzneimittel. Atac
    is a prescription medicine for the treatment of heart failure
    hypertension.
    Advised Swedish Orphan Biovitrum AB, an international biopharmaceutical company on the entry into a worldwide exclusive distribution agreement
    associated supply arrangements with Akcea Therapeutics in respect of Tegsedi
    Waylivra, two orphan medicines used to treat rare diseases.
    Advised an international biopharmaceutical company on the acquisition of a drug, including on the purchase of all rights, title
    interest in the product, for use worldwide
    a license back to the Sellers for their continued use in Japan.
    Previous Experience: Partner, Mayer Brown, 2000-2009
    Associate, Mayer Brown, 1991-2000
    Foreign Associate, New York office of an international law firm, 1997
    In-House Experience: General Counsel, HMV Media Group plc, 2000
  • Additional Links

Experience

  • Bar Admission & Memberships
    Admissions
    1993, England and Wales
  • Education & Certifications
    Other Education
    De Montfort University
    Class of 1989
    B.Sc.

Contact Fiona Adams

London Co-Managing Shareholder; Co-Chair, Global Corporate & Securities Practice at Greenberg Traurig, LLP
Not yet reviewed

The Shard, Level 8The Shard, Level 8, 32 London Bridge StreetLondon 10166England

Show on map
Fax: +44 (0)207 900 3632

Activity

Legal Community Contributions

Case type is required.
I am is required.
First name is required.
Last name is required.
A valid zip code is required.
Country is required.
State is required.
A valid city is required.
A valid email address is required.
A valid phone number is required.
Message is required.
0/1000 characters

By clicking the Submit button, you agree to the Terms of Use, Supplemental Terms and Privacy Policy. You also consent to be contacted at the phone number you provided, including by autodials, text messages and/or pre-recorded calls, from Lawyers.com and its affiliates and from or on behalf of attorneys you request or contact through this site. Consent is not a condition of purchase.

You should not send any sensitive or confidential information through this site. Emails sent through this site do not create an attorney-client relationship and may not be treated as privileged or confidential. The lawyer or law firm you are contacting is not required to, and may choose not to, accept you as a client. The internet is not necessarily secure and emails sent though this site could be intercepted or read by third parties.

This site is protected by reCAPTCHA. See Google’s Privacy Policy and Terms of Service.

Thank you! Your message has been successfully sent.

For your records, a copy of this email has been sent to test@test.com.

Summary of Your Message
Case Type:
I am a/an:
First Name:
Last Name:
City:
Zip Code or Postal Code:
State:
Country:
Phone Number:
Message:

Attorneys FAQs

  • How many attorneys are in this law firm?
    Greenberg Traurig, LLP has 2750 attorneys at this location.
  • What year was this attorney's law firm established?
    Greenberg Traurig, LLP was established in 1967.